서울대학교의과대학 학사
서울대학교의과대학 대학원 약리학 석사
서울대학교의과대학 대학원 약리학 박사
1991-1994 충북대학교 의과대학 전임강사, 조교수
1994-2001 서울대학교의과대학 전임강사, 조교수
2001–2006 서울대학교의과대학 부교수
2006– 현재 서울대학교의과대학 교수
1998-2000 미국 조지타운 대학교 Center for Drug Development Science, 전임의
2002–2007 서울대학교병원 임상약리실장
2008–2010 서울대학교의과대학 연구부학장
2006– 2017 서울대학교병원 임상시험센터 연구지원실장
2007– 서울대학교병원 임상약리학과장
2012 – 현재 서울대학교 의과대학 약리학교실 주임교수
2017 – 현재 서울대학교병원 임상시험센터 센터장
♦ 학회, 위원회 활동
- 대한임상약리학회 총무이사
- 대한약리학회 평위원
- 미국임상약리학회
- 심사평가원 비상근 위원 (2011)
♦ Educational Background
Seoul National University College of Medicine, Seoul, Korea : M.D.
Seoul National University Graduate School, Seoul, Korea : Ph.D.
♦ Professional Background
1991-1994 Department of Pharmacology, Chungbuk National Univ. College of Medicine / Lecturer, Assistant Professor
1994-2001 SNU College of Medicine / Lecturer, Assistant Professor
2001–2006 SNU College of Medicine / Associate Professor
2006– SNU College of Medicine / Professor
1998-2000 Center for Drug Development Science, Georgetown University Medical Center, Washington DC / Research Fellow
2002–2007 Dept. of Clinical Pharmacology & Therapeutics, Seoul National University / Director
2008–2010 Seoul National University College of Medicine / Associate Dean of Research Affairs
2006– 2017 Clinical Trials Center, Seoul National University Hospital / Director
2007– Dept. of Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine / Director
2012 – Dept. of Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine / Professor
2017 – Clinical Trials Center, Seoul National University Hospital / Director
Dr. Jang is a clinical pharmacologist interested in pharmacogenetics, pharmacokinetic/ pharmacodynamic (PK/PD) modeling, population PK, simulation of clinical trial and early clinical drug development methodologies. At Seoul National University Hospital, he is in charge of therapeutic drug monitoring consultation and execution of phase 1 clinical trials. His main research topics are application of imaging, genomic and metabolomic biomarkers to the optimal drug therapy and clinical development of new drugs. He is applying PK/PD modeling and simulation tools to explain the variabilities in drug response with the biomarkers.